Trials / Completed
CompletedNCT01040312
An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
A Prospective Observational Study of the Efficacy and Safety of CPT-11 Plus Platinum Analogues Regimens for UGT1A1 Genotype Guided Patients With Several Solid Tumors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 321 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the safety of CPT-11 plus platinum analogues (cisplatin, carboplatin and nedaplatin) regimens for patients with lung cancer, cervical cancer, ovarian cancer and gastric cancer.
Conditions
- Small Cell Lung Cancer
- Non-small Cell Lung Cancer
- Cervical Cancer
- Ovarian Cancer
- Gastric Cancer (Inoperable and Recurrent)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CPT-11 | CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog. |
| DRUG | Platinum analogues | Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs. |
Timeline
- Start date
- 2009-10-15
- Primary completion
- 2014-09-29
- Completion
- 2015-09-02
- First posted
- 2009-12-29
- Last updated
- 2019-05-23
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01040312. Inclusion in this directory is not an endorsement.